This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Hydrotalcite is an antacid indicated in the treatment of heartburn and excess gastric acid.
- Generic Name
- Hydrotalcite
- DrugBank Accession Number
- DB13322
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved, Experimental, Investigational
- Structure
Structure for Hydrotalcite (DB13322)
- Weight
- Average: 619.973
Monoisotopic: 617.940176 - Chemical Formula
- CH24Al2Mg6O24
- Synonyms
- Hydrotalcite
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetaminophen Hydrotalcite can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. Acetophenazine Hydrotalcite can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Alendronic acid The serum concentration of Alendronic acid can be decreased when it is combined with Hydrotalcite. Alfacalcidol The serum concentration of Hydrotalcite can be increased when it is combined with Alfacalcidol. Alimemazine Hydrotalcite can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Allopurinol The therapeutic efficacy of Allopurinol can be decreased when used in combination with Hydrotalcite. Amiodarone The risk or severity of hypotension can be increased when Hydrotalcite is combined with Amiodarone. Amlodipine The risk or severity of hypotension can be increased when Hydrotalcite is combined with Amlodipine. Amphetamine The serum concentration of Amphetamine can be increased when it is combined with Hydrotalcite. Amprenavir Hydrotalcite can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image SWECON SUSPENSION 100MG/ML Suspension 100 MG/ML Oral Y.S.P. INDUSTRIES (M) SDN BHD 2020-09-08 Not applicable Malaysia 
SWECON TABLET Tablet 500 mg Oral Y.S.P. INDUSTRIES (M) SDN BHD 2020-09-08 Not applicable Malaysia
Categories
- ATC Codes
- A02AD04 — Hydrotalcite
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as organic carbonic acids. These are compounds comprising the carbonic acid functional group.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Organic carbonic acids and derivatives
- Sub Class
- Organic carbonic acids
- Direct Parent
- Organic carbonic acids
- Alternative Parents
- Carbonate salts / Organic oxides / Organic aluminium salts / Hydrocarbon derivatives / Carbonyl compounds / Organic cations
- Substituents
- Aliphatic acyclic compound / Carbonate salt / Carbonic acid / Carbonyl group / Hydrocarbon derivative / Organic aluminium salt / Organic cation / Organic oxide / Organic oxygen compound / Organic salt
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 17432CG1KU
- CAS number
- 12304-65-3
- InChI Key
- BEBILBPAQKONJS-UHFFFAOYSA-L
- InChI
- InChI=1S/CH2O3.2Al.6Mg.12H2O.9O/c2-1(3)4;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h(H2,2,3,4);;;;;;;;;12*1H2;;;;;;;;;/q;2*+3;6*+2;;;;;;;;;;;;;9*-2/p-2
- IUPAC Name
- dialuminium(3+) ion hexamagnesium(2+) ion dodecahydrate carbonate nonaoxidandiide
- SMILES
- O.O.O.O.O.O.O.O.O.O.O.O.[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Al+3].[Al+3].[O-]C([O-])=O
References
- General References
- DIMDI Drug Product Information: Talidat (hydrotalcite) chewable tablets [Link]
- External Links
- ChemSpider
- 32698917
- 27221
- Wikipedia
- Hydrotalcite
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Dyspepsia 1 4 Completed Treatment Heartburn 1 4 Not Yet Recruiting Treatment NSAIDs-associated Intestinal Mucosal Injury 1 Not Available Recruiting Treatment Chronic Atrophic Gastritis (CAG) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule, liquid filled Oral 500 mg Tablet, chewable Oral 1000 MG Powder Tablet, chewable Oral Tablet, chewable Oral 500 mg Suspension Tablet, chewable Oral Suspension Oral 100 MG/ML Tablet, chewable Buccal 1000 mg Suspension Oral 1000 mg Suspension Oral Tablet, chewable Buccal 500 mg Tablet Oral 500 mg Suspension Oral 10 g - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 51.2 mg/mL ALOGPS logP 1.84 ALOGPS logP 0.25 Chemaxon logS -0.93 ALOGPS pKa (Strongest Acidic) 6.05 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 63.19 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 31.17 m3·mol-1 Chemaxon Polarizability 3.52 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at June 23, 2017 20:39 / Updated at June 02, 2021 20:04